Bill Alpert

The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging antibodies.

The company’s stock lost a third of its value Wednesday after the computer company disclosed that its auditor had resigned a week earlier.

Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. Amid a Madrid conference for Alzheimer’s researchers, Roche scientists talked to investors about the company’s experimental diagnostics and drugs for the devastating brain disease—including trontinemab, the first anti-Alzheimer’s antibody that easily crosses the blood-brain barrier. Roche plans to start pivotal Phase 3 trials of the drug next year.

The data show that firing CEOs to revive stock prices has increased in the past few years, as more activists appear on the scene and the option of selling the company diminishes.

To keep up with their fast Nvidia chips, artificial-intelligence data centers need fast networks. Apparently the growth that Arista reported Thursday night wasn’t as strong as its stock’s steep multiple demanded. Arista projected sales growth next year of about 16%.

Under the Chips Act the Commerce Dept. has awarded $36 billion to Intel, Micron Technology, and others. But no money has been disbursed.

From June to September, Ackman made two big moves in the hedge fund managed by his Pershing Square Capital.

The semiconductor maker is getting the money under the Chips Act. The cash will support the company’s planned investment of $65 billion to create a production cluster near Phoenix.

If you want to monitor your vital signs like an Olympic athlete, you should welcome a pact between glucose-monitor vendor DexCom and Oura smart rings.

Kennedy would oversee the National Institutes of Health as head of the Department of Health and Human Services.